MAJOR ACCOMPLISHMENTS IN 2014

• Clinical Trials DOUBLED: Information now available through genomic analysis has created an even greater need for new targeted investigational therapies to match genomic specificity of each patient. Available new trial targets include: PD-L1, PI3K, AKT, mTOR, c-MET, NEDD8, SMAC, Fhase, JAK 1/2, WEE1, Proteasome, Aurora A, MYC, XPO1, NF-kB and Mesothelin.

• Patient Enrollment to Clinical Trials INCREASED by 20%: Increased enrollment to clinical trials is expected to continue in 2015 due to the significant number of trials added during the last quarter of 2014. Mary Crowley offers clinical trials for all adult solid tumors and for Ewing’s Sarcoma in children and adolescents. Among the most common tumor types seen at the center are: Ovarian, Colorectal, Breast, Lung, Pancreatic and Hepatocellular.

• Cancer Immunotherapy Tested at Mary Crowley MOVING Toward FDA Approval Trial: Mary Crowley was instrumental in the phase I and II testing of a novel immunotherapy called FANG™ that is now poised for an FDA registration trial in 2015.

• Molecular Targeting Program ACCELERATED: Research physicians at Mary Crowley are rapidly adding to their Molecular Targeting tool-kit as more genomic information is revealed. The transforming aspect of the tool-kit is the alignment of diagnostic targets to available targeted therapies; the essence of personalization, that increases the probability of halting the patient’s cancer growth.

• Pediatric Ewing’s Clinical Trial ADVANCING to Phase II in Record Time: The Ewing’s Sarcoma Immunotherapy clinical trial that opened in 2012 has enrolled 17 adolescents from across the U.S. In record time, FDA is advancing the trial to phase II.

• Philanthropy GREW: Twelve NEW foundations/corporations brought first time gifts to Mary Crowley. Donors make our accomplishments possible!

• Crowley Phone App DEVELOPED for Physicians: Custom Mary Crowley iPhone App was developed for physicians that included clinical trial listing by disease type and molecular target. It contains inclusion/exclusion criteria and, within the App, the ability to e-mail a trial or contact a LIVE research staff member!
COMMUNITY ONCOLOGISTS PRESENT
It was a banner year for cross-fertilization of new ideas. Ten community oncologists exchanged cancer treatment approaches with the Mary Crowley team; (pictured above left to right): Drs. Thomas Hefferman, Jaya Juturi, Rohan Jeyarajah, Haskell Kirkpatrick, Joseph Kuhn, Kartik Konduri, Jeffrey Lamont, Robert Mennel, Michael Savin, and Joyce O’Shaughnessy. Treatment outcomes were discussed on various cancer types including: thyroid, lung, breast, pancreatic, and ovarian.

DR. NEMUNAITIS | GRAND ROUNDS
John Nemunaitis MD, presented at the University of Miami Grand Rounds on November 13, 2014; Targeting the Target in Cancer Management: bishRNA Platform.

DR. SENZER | ANNUAL SUMMIT
Neil Senzer MD, presented at the 1st Annual Summit on Practical Applications of Immune & Oncolytic Therapies in Oncology on July 18, 2014; providing the scientific background of the unique FANG™ vaccine.

DR. GHISLOLI | UNT HEALTH & SCIENCE
Maurizio Ghisoli MD, presented at the UNT Health and Science Center, Institute for Cancer Research on September 3, 2014; Mary Crowley’s “One Two Punch” in fighting Ewing’s Sarcoma.

APPOINTMENT | Staci Horvath, Research Operations Manager, was appointed as member of Association of Clinical Research Professional (ACRP’s) Global Conference Planning Committee (GCPC). The GCPC is responsible for the integrity of the Continuing Professional Development (CPD) function and content of the national conference.

UPCOMING PRESENTATIONS
February 2015: Staci Horvath is authoring an article on: Standardizing Principal Investigator Delegation Records: An Alternative Approach for Sites - being published in the Clinical Researcher February 2015 issue. The Clinical Researcher is a publication of ACRP that includes peer-reviewed articles.

February 17, 2015: Pat Brown, RN, MBA, and Director of Strategic Development for Mary Crowley is scheduled to speak at the Marco Island Community Group. The topic will be The State of Cancer and Research, Where We Were, Where We Are and Where We Are Going.

March 28, 2015: Dr. Jonathan Oh is scheduled to present for the Society of Gynecologic Oncology at the Annual Meeting on Women’s Cancer in Chicago, IL, on the Randomized Phase II trial of FANG™.


WELCOME OUR NEW PHYSICIAN ASSISTANT
Mary Crowley is pleased to welcome Leah Plato, PA-C, MPH, CCRP to the research investigative team. She will work closely with all the physician investigators as well as the nursing staff in support of the center’s patient centered culture. Leah received her Master’s in Health Sciences (MSHS) at George Washington University in Washington, D.C. and her Postgraduate Oncology Fellowship at the University of Texas, MD Anderson Cancer Center in Houston, Texas. In her capacity as a Research Physician Assistant, she has most recently served as the Clinical Trial Sub-Investigator at the Karmanos Cancer Institute in Detroit, Michigan.
Ewing’s Supporters REACH $1M for NEW Investigational Therapy In 2014, THIRTEEN gifts, totaling $1 Million dollars, were given by families, friends and private foundations across the U.S. to accelerate the development of a new targeted investigational therapy for Ewing’s Sarcoma. Thirteen-year-old Sam Day and his family from Portland, Oregon, and longtime supporter and Executive Director of the Rutledge Foundation, Laura Rutledge, from Ft. Worth, Texas, presented the latest check for $150,000 to Mary Crowley Cancer Research Centers on December 16th, 2014. Pictured above, left to right: Dr. Maurizio Ghisoli, Shannon Cagnina COO of Mary Crowley, Robert Day, Loma Day, Natalie Day, Sam Day, Laura Rutledge, Executive Director of the Rutledge Foundation and Ellen Dearman VP of Development at Mary Crowley.

Allison’s Hope Foundation HITS $1M for Mary Crowley Now in its tenth year, Allison’s Hope Foundation reached a monumental goal of raising $1 million for cancer research at Mary Crowley. On November 3rd, 2014, the foundation presented a check in the amount of $100,000 to Mary Crowley Cancer Research Center that hit their $1 Million mark!

“Today was a celebration for all cancer patients who, through cutting edge research were given another chance for extended survival. Without the focus, determination and generosity of Allison’s Hope Foundation over the past 10 years, this would not have been possible for many patients,” says a spokesperson from Mary Crowley.

Innovative Clinical Trial Development: A Total of $1.3M was contributed to Mary Crowley in 2014 so that advanced cancer patients, having failed all standard treatments, could receive one of the newer investigational therapies.

Benevolence: Approximately $38,000 was donated to our benevolence program that aids patients and families experiencing financial hardships.

Nursing Programs: Gifts of over $100,000 were given to support our nurses and related programs. Mary Crowley’s oncology nursing teams are nationally recognized experts in understanding the needs of patients who are receiving DNA-based therapies.

Physician Leadership: Gifts of $300,000 were given to support Mary Crowley’s physician leadership team. Donors respect the unique role medical investigators serve when developing an innovative clinical trial program.

Left to right Denise Gualdoni, Kate Allaria, and Linda Cassens of AHF

Our Gratitude To 2014 Partners Who Selected Mary Crowley As Beneficiaries:

- American Electric Power Charity Golf & Softball Tournament
- BIG HOPE 1
- Colon Cancer Alliance, UNDY 5000
- Communities Foundation - North Texas Giving Day
- Dallas Stars Hockey Fights Cancer
- Equestrians For Life
- Haul Hope for Mary Crowley
- Kroger’s Rewards Program

SAVE THE DATE in 2015! The Event of the Year is Silver Dollar At The Ranch on May 16, 2015 benefitting Mary Crowley and Cook Children’s. Plan now for a spectacular western evening on a working ranch! For more information and tickets, visit silverdollarattheranch.com
LOSING ONE OF OUR OWN IN 2014

Joseph Allen Kuhn, M.D. was an extraordinary man, and no words, images or means of communication could ever express the depth of his greatness. Despite this common sentiment, we nevertheless attempt to pay tribute to an eminent man. As a skilled surgeon, Dr. Kuhn was frequently called upon by Mary Crowley to surgically remove the most difficult tumors from cancer patients. His soft demeanor instantly put patients at ease, and during their recovery phase they experienced the highest level of medical attention, gentleness and humility, for which he gave all the credit to God as the ultimate healer. Joe, as he was called by many, was no different with his colleagues. All knew him as a devoted family man, a brilliant scientist of great curiosity, a surgeon committed to innovating surgical techniques for cancer patients, a man of strong Christian faith, and a faithful friend and confidant.

His contribution as a surgical oncologist, clinical trial Investigator, and key member of the Strategic Development team at Mary Crowley created a lasting legacy. Dr. Kuhn’s creative patient care through surgical, medical oncology, and clinical research technologies made a significant impact toward advancing new treatment. A strong advocate for patients, he faithfully served on the Mary Crowley Institutional Review Board for many years. Through his years of scientific research, he was most proud of work completed with his two daughters that challenged Darwinism in hopes that some would ultimately recognize a Creator of all things wonderful. His devoted wife of 36 years, Mollie, continues to serve as a Trustee for Mary Crowley Cancer Research Centers.

Dr. Kuhn completed medical school at UTMB in Galveston, surgical residency at Baylor University Medical Center, and a Surgical Oncology fellowship at the City of Hope in California. He was a board-certified oncological surgeon and an esteemed member of the medical staff at Baylor University Hospital and Medical City Dallas.

Mary Crowley Trustee Dr. Charles Brunicardi, Vice-chairman of Surgery at UCLA Medical School said it well,

“Dr. Kuhn was a great surgeon and the finest of gentleman. It was an honor to call him a colleague and friend. He will be missed.”